Gonioscopy-assisted Transluminal Trabeculotomy (GATT) combined phacoemulsification surgery: Outcomes at a 2-year follow-up.
Wan Yue, Cao Kai, Wang Jin, Sun Yunxiao, Du Rong, Wang Ziyi, Zhang Jidi, Wang Huaizhou, Wang Ningli
AI Summary
GATT combined with cataract surgery effectively and safely lowered eye pressure and medication use for 24 months in patients with glaucoma and cataracts, offering a good treatment option.
Abstract
Background/objectives: This study aimed to provide a 24-month follow-up on the surgical success and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification and intraocular lens (IOL) implantation in the treatment of patients with primary open-angle glaucoma (POAG) combined cataract.
Subjects/Methods
We included 124 consecutive cases of POAG with microcatheter-assisted GATT or GATT combined with phacoemulsification and IOL implantation at Beijing Tongren Eye Centre between October 2019 and November 2020. Main outcome measures included surgical success rate, changes in IOP, number of antiglaucoma medications, best corrected visual acuity (BCVA), postoperative complications at baseline, and follow-up period of up to 24 months.
Results
In total, 58 eyes received GATT combined with phacoemulsification surgery and 66 eyes received GATT alone. The overall qualified success rate was 86.21% for eyes with GATT combined with phacoemulsification surgery, and 83.48% for eyes with GATT only at 24 months. IOP was reduced from 26.40 ± 6.37 mmHg on 3.12 ± 0.80 medications preoperatively to 14.61 ± 2.28 mmHg on 0.27 ± 0.71 medications at 12 months and 16.08 ± 2.38 mmHg on 0.45 ± 0.96 medications at 24 months after combined surgery. Additionally, mean BCVA improved from 0.75 ± 0.43 logMAR units preoperatively to 0.22 ± 0.18 logMAR units 24 months after combined surgery. No vision-threatening complications occurred during the 24-month follow-up.
Conclusions
The 24-month follow-up results of our study suggest that GATT combined with cataract surgery is a safe and effective treatment for decreasing IOP and number of medications in patients with POAG combined cataract.
MeSH Terms
Shields Classification
Key Concepts6
Gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification surgery achieved an overall qualified success rate of 86.21% at 24 months in patients with primary open-angle glaucoma (POAG) combined with cataract.
Gonioscopy-assisted transluminal trabeculotomy (GATT) alone achieved an overall qualified success rate of 83.48% at 24 months in patients with primary open-angle glaucoma (POAG).
Intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) combined with cataract decreased from 26.40 ± 6.37 mmHg preoperatively to 16.08 ± 2.38 mmHg at 24 months after gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification surgery.
The number of antiglaucoma medications in patients with primary open-angle glaucoma (POAG) combined with cataract decreased from 3.12 ± 0.80 preoperatively to 0.45 ± 0.96 at 24 months after gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification surgery.
Mean best corrected visual acuity (BCVA) improved from 0.75 ± 0.43 logMAR units preoperatively to 0.22 ± 0.18 logMAR units 24 months after gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification surgery in patients with primary open-angle glaucoma (POAG) combined with cataract.
No vision-threatening complications occurred during the 24-month follow-up period after gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification surgery in patients with primary open-angle glaucoma (POAG) combined with cataract.
Related Articles5
XEN Gel Stent Versus Nonpenetrating Deep Sclerectomy in Ocular Hypertension and Open Angle Glaucoma Patients.
Cohort StudyComplications of micro-invasive glaucoma surgery.
ReviewMicroinvasive Glaucoma Stent (MIGS) Surgery With Concomitant Phakoemulsification Cataract Extraction: Outcomes and the Learning Curve.
Observational StudyComparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery.
Cohort StudyCataract surgery combined with glaucoma surgery.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.